Ro-3306

Catalog No.S7747

Ro-3306 Chemical Structure

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Size Price Stock Quantity  
USD 127 In stock
USD 397 In stock
USD 997 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • HeLa cells were untreated or treated with either colcemid (10 μg/ml for 16 h), RO-3306 (9 μM for 16 h), or both colcemid and RO-3306, as indicated. Cells were then lysed, and proteins were detected by Western analysis.

    J Cell Biol, 2015, 209(2): 221-34 . Ro-3306 purchased from Selleck.

    A, Expression of IFIT3 in HeLa cells pretreated with 5 μM RO-3306 for 12 hours and then stimulated with type I IFN (1,000 units/ml) for 8 hours. The cells were collected and total RNA was extracted for the detection of IFIT3 mRNA. Results are the relative expression levels of IFIT3 mRNA normalized to endogenous GAPDH mRNA levels. B, Expression of IFI27 in HeLa cells measured in the same samples as in A.

    Arthritis Rheumatol, 2016, 68(5):1222-32.. Ro-3306 purchased from Selleck.

  • AML cells were treated with AZ20 in the absence or presence of RO-3306 (RO) for 24 h. Cells were then subjected to annexin V-FITC/PI staining and flow cytometry analyses. Combined treatment was compared to AZ20 treatment alone using pair-wise two-sample t-test. ***Indicates p < 0.001.

    Sci Rep, 2017, 7:41950. Ro-3306 purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Targets
CDK1 [1]
(Cell-free assay)
PKCδ [1]
(Cell-free assay)
SGK [1]
(Cell-free assay)
ERK [1]
(Cell-free assay)
20 nM(Ki) 318 nM(Ki) 497 nM(Ki) 1980 nM(Ki)
In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human NCI-SNU-1 cell NIK4fI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLwd3M4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkezNFk2KM7:TR?= NHHhdmxUSU6JRWK=
human H460a cells M3vrOHBzd2yrZnXyZZRqd25iYYPzZZk> M13Pd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NIEh[2WubIOsJGlEPTB;MT6wOEDPxE1? NHX6XWwyPzNyM{SyNS=>
human MDA435 cells NUXsNVNsWHKxbHnm[ZJifGmxbjDhd5NigQ>? MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQUSzOUBk\WyuczygTWM2OD1zLkG0JO69VQ>? NFzKN5oyPzNyM{SyNS=>
human HCT116 cells MX3Qdo9tcW[ncnH0bY9vKGG|c3H5 NH;rXJVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{whUUN3ME2xMlE1KM7:TR?= NUHvW5JLOTd|MEO0NlE>
human H4 cell NVHPZlVmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml34TY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMUW4O|Uh|ryP MXPTRW5ITVJ?
human PA-1 cell NUS5fZJwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyOlU1KM7:TR?= MWjTRW5ITVJ?
human T98G cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{XGXGlvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|Y5OTJizszN MWjTRW5ITVJ?
human SW1710 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHix[YZKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjF2MEig{txO MXvTRW5ITVJ?
human U251 cell NV;IcpZ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3PrZWlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlM4PzFizszN NGPkWINUSU6JRWK=
human ALL-PO cell NGG0WXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MorSTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4Phfg+9lCCLQ{WwQVEvQTB6MUOg{txO MkLmV2FPT0WU
human RKO cells Mn3KVJJwdGmoZYLheIlwdiCjc4PhfS=> MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyxiSVO1NF0zKM7:TR?= M2HWdlE4OzB|NEKx
human SK-N-DZ cell MnzFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHXPeZFKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjBzOEe2JO69VQ>? MorVV2FPT0WU
human A4-Fuk cell NV\Gbmg3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFU3ODRizszN MYPTRW5ITVJ?
human SW480 cells NEOzXlVRem:uaX\ldoF1cW:wIHHzd4F6 M2LlWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2e0PFAh[2WubIOsJGlEPTB;Mj6yJO69VQ>? M4TBfVE4OzB|NEKx
human 639-V cell NXfSWXdmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLVbFdKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzV|NzFOwG0> NX3KUI1CW0GQR1XS
human Hs-578-T cell NXnIbFN3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkfrTY5pcWKrdHnvckBw\iCqdX3hckBJey13N{itWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd5OUmg{txO M1zYZnNCVkeHUh?=
human UM-UC-3 cell MnfjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVX0OYRrUW6qaXLpeIlwdiCxZjDoeY1idiCXTT3VR{0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD1{LkezPVM3KM7:TR?= NV;vNJIxW0GQR1XS
human BPH-1 cell M4fVTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGPkXI9KdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46PzR3NTFOwG0> M33QUnNCVkeHUh?=
human 5637 cell M1HUemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJFU3OzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkC4OVMzKM7:TR?= NIXme4xUSU6JRWK=
human 8-MG-BA cell M{Hod2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTWSW5IUW6qaXLpeIlwdiCxZjDoeY1idiB6LV3HMWJCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD1|LkG0NFQ6KM7:TR?= MYXTRW5ITVJ?
human HCT116 cells M3:2WGN6fG:2b4jpZ:Kh[XO|YYm= NVHZ[JRlPSCmYYnz NVTRWo5GS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[XoxvJygTWM2OD1|LkKg{txO MkTJNlI{OjZzNki=
human LB1047-RCC cell NGG0VFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXfLcIl{UW6qaXLpeIlwdiCxZjDoeY1idiCOQkGwOFcuWkOFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz6yN|UxOSEQvF2= NI\wPVZUSU6JRWK=
human KOSC-2 cell NXW5dphiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGP1bXNKdmirYnn0bY9vKG:oIHj1cYFvKEuRU1OtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDR4Nk[yJO69VQ>? MYLTRW5ITVJ?
human COR-L88 cell MnThS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX6xUZYzUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFg5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy52N{W4N{DPxE1? NFHUbGFUSU6JRWK=
human PSN1 cell M{DYS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVHuc5AzUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yODhyNTFOwG0> NEjKeFVUSU6JRWK=
human LXF-289 cell M2LXOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW[zTmFrUW6qaXLpeIlwdiCxZjDoeY1idiCOWF[tNlg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC5{MUe2JO69VQ>? M1HONHNCVkeHUh?=
human MN-60 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NILIc21KdmirYnn0bY9vKG:oIHj1cYFvKE2QLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{PzZ{MzFOwG0> MkDiV2FPT0WU
human NEC8 cell MnjBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml63TY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60O|A4PiEQvF2= NI\hZXZUSU6JRWK=
human SJSA1 cells MWDQdo9tcW[ncnH0bY9vKGG|c3H5 NX:5NFRDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTTnNCOSClZXzsd{whUUN3ME20MlU2KM7:TR?= M2rZdFE4OzB|NEKx
human NCI-H2405 cell M3PybGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVz2XWFwUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1ODViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke0OFk{KM7:TR?= MXfTRW5ITVJ?
human YH-13 cell NFPOSIpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1T5TmlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc2Pzd4IN88US=> M3vONXNCVkeHUh?=
human SK-MEL-2 cell Mn;CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xQTZ|MjFOoI0> Mn;5V2FPT0WU
human NB13 cell MnjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnjCTY5pcWKrdHnvckBw\iCqdX3hckBPSjF|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6zNlc5PiEQvF2= NX:2NXZuW0GQR1XS
human GAMG cell MlzrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWn1bYE5UW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzF3IN88US=> MkX3V2FPT0WU
human NCI-H1792 cell Mme0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moj6TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjR5OUW0JO69VQ>? NHPrVmtUSU6JRWK=
human KP-4 cell M2\Ffmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M37XPGlvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlk5OjNizszN M1nafXNCVkeHUh?=
human HGC-27 cell NUXBS3lNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3TxZmlvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OzB5NzFOwG0> NWfmZ|JYW0GQR1XS
human GCT cell NV\BWFU{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkjmTY5pcWKrdHnvckBw\iCqdX3hckBIS1RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lki1NVIyKM7:TR?= NF3pRWRUSU6JRWK=
human PFSK-1 cell NYi1dWNFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmHjTY5pcWKrdHnvckBw\iCqdX3hckBRTlONLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg3OTZ6IN88US=> MoPHV2FPT0WU
human A172 cell MoXDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkjRTY5pcWKrdHnvckBw\iCqdX3hckBCOTd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT65NFc6KM7:TR?= M3vBdHNCVkeHUh?=
human HO-1-N-1 cell NX;afYNmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF60bXpKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57NUSyOUDPxE1? Ml;0V2FPT0WU
human HN cell M33D[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV21XldQUW6qaXLpeIlwdiCxZjDoeY1idiCKTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuPVcxQTdizszN NWi2dm0{W0GQR1XS
human IST-MES1 cell M3OxV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVPJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2PRWOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PzV{MTFOwG0> MWDTRW5ITVJ?
human TGW cell NXrBenFjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;HTY5pcWKrdHnvckBw\iCqdX3hckBVT1diY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkC1OlgzKM7:TR?= M3L1VnNCVkeHUh?=
human COR-L23 cell MonJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM4OzVizszN NX\6VZdNW0GQR1XS
human D-566MG cell NVTodYNXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTZ4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlc5QDd|IN88US=> MorxV2FPT0WU
human SKG-IIIa cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDiUmdKdmirYnn0bY9vKG:oIHj1cYFvKFONRz3JTWliKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi56NUW3NkDPxE1? NIq1SpRUSU6JRWK=
human NCI-H446 cell M335dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnHrTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES0OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODF6MTFOwG0> MlXVV2FPT0WU
human KYSE-270 cell NGn3cVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXRT2NbUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVI4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEO4O|Ih|ryP MYPTRW5ITVJ?
human CAL-39 cell NIfLcFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jYeGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PTJ2IN88US=> NVnZUolxW0GQR1XS
human IST-SL1 cell M4LlRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHTNcGlKdmirYnn0bY9vKG:oIHj1cYFvKEmVVD3TUFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjR|M{S5JO69VQ>? NXvHUVd[W0GQR1XS
human SF539 cell M3X3cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPvO2s6UW6qaXLpeIlwdiCxZjDoeY1idiCVRkWzPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTVzOUeg{txO NXL1RlFlW0GQR1XS
human TE-1 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnITY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PVA6OSEQvF2= MXfTRW5ITVJ?
human NB10 cell M3fMe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lkm4O|U5KM7:TR?= MVjTRW5ITVJ?
human 8505C cell MmH6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33zXGlvcGmkaYTpc44hd2ZiaIXtZY4hQDVyNVOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlk6QDF5IN88US=> M13VWnNCVkeHUh?=
human DB cell M4LnWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXTVW46UW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFEyOzFizszN NVjIUZhIW0GQR1XS
human NCI-H28 cell NHXBelZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWnoRVcyUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC53OUi4OEDPxE1? NEXvfXJUSU6JRWK=
human LOXIMVI cell NXLEWZZPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY{PzBzIN88US=> MoHxV2FPT0WU
human ME-180 cell Mn7wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFflTIdKdmirYnn0bY9vKG:oIHj1cYFvKE2HLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVgvQDB|OUWg{txO MoPyV2FPT0WU
human ES3 cell MkLXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mkj5TY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkGyO|k1KM7:TR?= MnjrV2FPT0WU
human SK-N-FI cell MkXuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnzOTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLV\JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41OTZ7OTFOwG0> M1HGdHNCVkeHUh?=
human NBsusSR cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NI\lfXNKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{M{G4JO69VQ>? M3P6bnNCVkeHUh?=
human MCF7 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnmxTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUGuNVg1QSEQvF2= NUDXWVRvW0GQR1XS
human A549 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPSPXJKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4zODZizszN NFz6TXlUSU6JRWK=
human HuP-T4 cell MnPUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn:xTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE41OjdzIN88US=> MmniV2FPT0WU
human HSC-2 cell M{HjVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{TOSmlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNUw4QDR{IN88US=> NFqyXYFUSU6JRWK=
human A253 cell M4nFcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT6yPFM1KM7:TR?= NXjmcYhkW0GQR1XS
human HCT-116 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mk\XTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUiuNFA1OyEQvF2= NXPXZmdbW0GQR1XS
human HCT-116 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmSxTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPjZ6IN88US=> MVLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
+ Expand

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
Cell Research:[3]
+ Expand
  • Cell lines: MDA-MB-231 cell line
  • Concentrations: 20 μM
  • Incubation Time: 72 h
  • Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL warmed (36.98 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 351.45
Formula

C18H13N3OS2

CAS No. 872573-93-8
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

CDK Signaling Pathway Map

Related CDK Products

Tags: buy Ro-3306 | Ro-3306 supplier | purchase Ro-3306 | Ro-3306 cost | Ro-3306 manufacturer | order Ro-3306 | Ro-3306 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID